Conference: Wednesday 25 and Thursday 26 September 2019
Workshop: Tuesday 24th September 2019
Location: Copthorne Tara Hotel, London, UK
Chaired by Michel Mikhail, International Expert Regulatory Affairs, Global Expert Biosimilars
Discussing future regulatory, commercial and legal challenges of biosimilars
SMi Group are delighted to announce the 10th annual Biosimilars Conference taking place on 25th and 26th September 2019. This year’s event will be our first global event taking place in London, UK. The event’s focus is to highlight the current challenges in the biosimilars market and discuss current undergoing plans or developments to overcome these challenges.
The biosimilars market is forecasted to reach USD$23.6B by 2023 at a compound annual growth rate (CAGR) of 31.70%. Factors driving the increase of this market include growing demand for biosimilar drugs due to their cost-effectiveness, growing incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.
With the expiry dates of major patents fast approaching, the emerging gap in the market for biosimilars is now a major attraction for manufacturers. As the availability of biosimilars could potentially reduce direct spending by USD$54B by 2026, the question is what can current biosimilar producing companies do to join this market to benefit the patients, physicians and investors?
BENEFITS OF ATTENDING
- HEAR about current strategies under development to overcome challenges with patents currently faced by many biosimilar developers
- DISCUSS the possible changes in regulatory approval of biosimilars in the UK post Brexit, and how this will impact market entry
- EXPLORE the latest methods in use to maintain the relationship between stakeholders, doctors and patients, with the influence of governing bodies
- REVIEW FDA regulations for the approval of Biosimilars and the latest approvals
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 24th September 2019, Copthorne Tara Hotel, Central London, UK
A: US-FDA Interchangeability Guideline
08.30 – 12.30
Workshop Leader: Michel Mikhail, International Expert Regulatory Affairs, Global Expert of Biosimilars
B: Global Development of Biosimilars – what can the US learn from Europe’s Strategies to promote biosimilar uptake
13:30 – 17:30
Workshop Leader: Rodeina Challand, General Manager, Challand Biosimilar Consulting
WHO SHOULD ATTEND?
Presidents, Vice Presidents, Managing Directors, Directors, Associate Directors, Chiefs, Heads, Principals, Managers and Analysts of:
Research and Development
For information and to register visit http://www.biosimilars-europe.com/biochem